Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling
复制标题
DOI：
10.1016/s1535-6108(02)00032-6
复制
发表时间：
2002-03-01
期刊：
影响因子：
50.3
通讯作者：
Downing, JR
中科院分区：
文献类型：
--
作者：
Yeoh, EJ;Ross, ME;Downing, JR
儿科急性淋巴细胞白血病（ALL）的治疗是基于根据患者复发风险调整治疗强度的概念。为了确定基因表达谱是否可以增强风险分配，我们使用寡核苷酸微阵列分析了360名儿科ALL患者白血病原细胞的基因表达模式。不同的表达谱确定了每一种预后重要的白血病亚型，包括T-ALL、E2A-PBX1、BCR-ABL、TEL-AML1、MLL重排和超二倍体bbb50染色体。此外，根据其独特的表达谱确定了另一个ALL亚组。对包含表达特征的基因的检查为这些白血病亚群的生物学提供了重要的见解。此外，在一些基因亚群中，表达谱确定了那些最终治疗失败的患者。因此，单一的表达谱平台应该能提高儿科ALL患者的准确风险分层。
Treatment of pediatric acute lymphoblastic leukemia (ALL) is based on the concept of tailoring the intensity of therapy to a patient's risk of relapse. To determine whether gene expression profiling could enhance risk assignment, we used oligonucleotide microarrays to analyze the pattern of genes expressed in leukemic blasts from 360 pediatric ALL patients. Distinct expression profiles identified each of the prognostically important leukemia subtypes, including T-ALL, E2A-PBX1, BCR-ABL, TEL-AML1, MLL rearrangement, and hyperdiploid >50 chromosomes. In addition, another ALL subgroup was identified based on its unique expression profile. Examination of the genes comprising the expression signatures provided important insights into the biology of these leukemia subgroups. Further, within some genetic subgroups, expression profiles identified those patients that would eventually fail therapy. Thus, the single platform of expression profiling should enhance the accurate risk stratification of pediatric ALL patients.